AUTHOR=Coker-Ayo Oreoluwa O. , Nathaniel Samuel I. , Poupore Nicolas , Bailey-Taylor Melissa J. , Roley Laurie Theriot , Goodwin Richard L. , McPhail Brooks , Russ-Sellers Rebecca , Nathaniel Thomas I. 

TITLE=Sex Differences in Demographic and Pharmacological Factors in Alzheimer Patients With Dementia and Cognitive Impairments

JOURNAL=Frontiers in Behavioral Neuroscience

VOLUME=16

YEAR=2022

URL=https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2022.828782

DOI=10.3389/fnbeh.2022.828782

ISSN=1662-5153

ABSTRACT=<sec><title>Objective</title><p>The current study investigates sex differences associated with pharmacological and demographic characteristics in Alzheimer patients (AD) with dementia (ADD) or mild cognitive impairment (MCI).</p></sec><sec><title>Method</title><p>A retrospective analytical approach was used to analyze data from 45,696 AD patients with MCI or ADD. The univariate analysis was used to determine differences in demographic, and pharmacological characteristics for male and female ADD and MCI-AD patients. Multivariate analysis was used to predict specific pharmacological and demographic factors that are associated with male and female MCI and ADD patients.</p></sec><sec><title>Result</title><p>In the adjusted analysis for male patients, Hispanics [0.166,0.020 – 1.355, <italic>P</italic> = 0.094] or African Americans [OR = 2.380, 95% CI,2.120 – 2.674, <italic>P</italic> &lt; 0.001], were more likely to have MCI-AD and be treated with galantamine [OR = 0.559, 95% CI, 0.382 – 0.818, <italic>P</italic> = 0.003], donepezil [OR = 1.639, 95% CI,1.503 – 1.787, <italic>P</italic> &lt; 0.001], rivastigmine [OR = 1.394, 95% CI,1.184 – 1.642, <italic>P</italic> &lt; 0.001], olanzapine [OR = 2.727, 95% CI,2.315 – 3.212, <italic>P</italic> &lt; 0.001], risperidone [OR = 2.973, 95% CI,2.506 – 3.526, <italic>P</italic> &lt; 0.001], present with increasing age [1.075,1.071 – 1.079, <italic>P</italic> &lt; 0.001], and are on tobacco use [OR = 1.150, 95% CI,1.054 – 1.254, <italic>P</italic> = 0.002]. For female patients, buspirone [OR = 0.767, 95% CI, 0.683 – 0.861, <italic>P</italic> &lt; 0.001] and a history of alcohol (ETOH) use [OR = 0.484, 95% CI, 0.442 – 0.529, <italic>P</italic> &lt; 0.001] were associated with MCI-AD. Increasing age [OR = 1.096, 95% CI, 1.093 – 1.100, <italic>P</italic> &lt; 0.001], donepezil [OR = 2.185, 95% CI, 2.035 – 2.346, <italic>P</italic> &lt; 0.001], memantine [OR = 2.283, 95% CI, 2.104 – 2.477, <italic>P</italic> &lt; 0.001] aripiprazole [OR = 1.807, 95% CI, 1.544 – 2.113, <italic>P</italic> &lt; 0.001] olanzapine [OR = 2.289, 95% CI, 1.986 – 2.640, <italic>P</italic> &lt; 0.001] risperidone [OR = 2.548, 95% CI, 2.246 – 2.889, <italic>P</italic> &lt; 0.001] buspirone [OR = 0.767, 95% CI, 0.683 – 0.861, <italic>P</italic> &lt; 0.001] escitalopram [OR = 1.213, 95% CI,1.119 – 1.315, <italic>P</italic> &lt; 0.001] African Americans [OR = 1.395, 95% CI, 1.268 – 1.535, <italic>P</italic> &lt; 0.001] and tobacco use [OR = 1.150, 95% CI, 1.073 – 1.233, <italic>P</italic> &lt; 0.001] were associated with ADD.</p></sec><sec><title>Conclusion</title><p>Our findings reveal that MCI-AD patients were more likely to be Hispanics or African American males treated with rivastigmine, olanzapine and citalopram. African American females were associated with ADD and more likely to be treated with buspirone and presented with a history of ETOH. This finding suggests the need for a pharmacological treatment approach encompassing sex-sensitive strategies for MCI-AD and ADD patients.</p></sec>